Clinical Trials Browser

INDUSTRY × Hematologic Neoplasms × 30 days × Clear all

Neoplasms, Hematologic Neoplasms

NCT04067336 2026-04-21

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03328078 2026-04-16

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Phase 1/2 Recruiting

152 enrolled

LymphoidOther hematologic neoplasm

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Recurrence, Hematologic Neoplasms

NCT07504458 2026-04-16

QUATRO-APL

Phase 3 Recruiting

150 enrolled

Other hematologic neoplasm

Hematologic Diseases, Leukemia, Neoplasms, Leukemia, Promyelocytic, Acute, Hematologic Neoplasms

NCT06823167 2026-04-15

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

Phase 1 Recruiting

117 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT07216443 2026-04-15

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 2 Recruiting

80 enrolled

MyeloidOther hematologic neoplasmOther neoplasm

Acute Disease, Bone Marrow Diseases, Disease, Graft vs Host Disease, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Precancerous Conditions, Preleukemia, Syndrome, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Disease Attributes

NCT06001788 2026-04-14

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1 Recruiting

171 enrolled

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT07195916 2026-04-14

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Phase 1 Recruiting

280 enrolled

DermatologicGenitourinaryLymphoidOther hematologic neoplasm

Carcinoma, Renal Cell, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT03145181 2026-04-13

MajesTEC-1

Phase 1/2 Active not recruiting

302 enrolled 2 FDA

Other hematologic neoplasm

Hematologic Neoplasms

NCT03399799 2026-04-13

MonumenTAL-1

Phase 1 Active not recruiting

279 enrolled 2 FDA

Other hematologic neoplasm

Hematologic Neoplasms

NCT03486873 2026-04-13

MK-3475-587

Phase 3 Recruiting

3,500 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT04557098 2026-04-13

MajesTEC-1

Phase 2 Active not recruiting

194 enrolled 2 FDA

Other hematologic neoplasm

Hematologic Neoplasms

NCT04634552 2026-04-13

MonumenTAL-1

Phase 2 Recruiting

510 enrolled 2 FDA

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT04696809 2026-04-13

A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Active not recruiting

40 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT04728893 2026-04-13

MK-1026-003

Phase 2 Recruiting

490 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Hematologic Neoplasms

NCT07523555 2026-04-13

ADAPT-HEM

Phase 1/2 Recruiting

96 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Leukemia, Plasma Cell, Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07007312 2026-04-09

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Phase 3 Recruiting

1,300 enrolled

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04684108 2026-04-07

SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

Phase 1 Active not recruiting

61 enrolled

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Hematologic Neoplasms

NCT02494258 2026-04-02

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Phase 2 Completed

5 enrolled 10 charts

Other hematologic neoplasm

Hematologic Diseases, Neoplasms, Hematologic Neoplasms

NCT06870487 2026-04-01

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

Phase 1 Active not recruiting

6 enrolled

DermatologicHead & NeckLymphoidOther hematologic neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Hodgkin Disease, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Skin Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT05753501 2026-03-27

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Phase 1 Active not recruiting

135 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT06645886 2026-03-25

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

Phase 1 Active not recruiting

13 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

Clinical Trials

Durvalumab and Tremelimumab for Pediatric Malignancies

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

QUATRO-APL

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

MajesTEC-1

MonumenTAL-1

MK-3475-587

MajesTEC-1

MonumenTAL-1

A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

MK-1026-003

ADAPT-HEM

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies